<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xml:lang="EN" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?origin publisher?><?properties no_embargo?><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Pflugers Arch</journal-id><journal-title>Pflugers Archiv </journal-title><issn pub-type="ppub">0031-6768</issn><issn pub-type="epub">1432-2013</issn><publisher><publisher-name>Springer-Verlag</publisher-name><publisher-loc>Berlin/Heidelberg</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">676</article-id><article-id pub-id-type="doi">10.1007/s00424-009-0676-9</article-id><article-categories><subj-group subj-group-type="heading"><subject>Molecular and Genomic Physiology</subject></subj-group></article-categories><title-group><article-title>Peroxisome proliferator-activated receptor &#x003b2; activation promotes myonuclear accretion in skeletal muscle of adult and aged mice</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Giordano</surname><given-names>C.</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Rousseau</surname><given-names>A. S.</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wagner</surname><given-names>N.</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gaudel</surname><given-names>C.</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Murdaca</surname><given-names>J.</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Jehl-Pi&#x000e9;tri</surname><given-names>C.</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sibille</surname><given-names>B.</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Grimaldi</surname><given-names>P. A.</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Lopez</surname><given-names>P.</given-names></name><address><phone>+33-493-377796</phone><fax>+33-493-815432</fax><email>Pascal.LOPEZ@unice.fr</email></address><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1">INSERM U907, Universit&#x000e9; de Nice-Sophia Antipolis, Facult&#x000e9; de M&#x000e9;decine, 28 avenue de Valombrose, 06107 Nice, France </aff></contrib-group><pub-date pub-type="epub"><day>5</day><month>5</month><year>2009</year></pub-date><pub-date pub-type="ppub"><month>9</month><year>2009</year></pub-date><volume>458</volume><issue>5</issue><fpage>901</fpage><lpage>913</lpage><history><date date-type="received"><day>13</day><month>2</month><year>2009</year></date><date date-type="rev-recd"><day>1</day><month>4</month><year>2009</year></date><date date-type="accepted"><day>21</day><month>4</month><year>2009</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2009</copyright-statement></permissions><abstract xml:lang="EN"><p>We reported recently that peroxisome proliferator-activated receptor &#x003b2; (PPAR&#x003b2;) activation promotes a calcineurin-dependent exercise-like remodelling characterised by increased numbers of oxidative fibres and capillaries. As physical exercise also induces myonuclear accretion, we investigated whether PPAR&#x003b2; activation alters myonuclear density. Transgenic muscle-specific PPAR&#x003b2; over-expression induced 14% increase of myonuclear density. Pharmacological PPAR&#x003b2; activation promoted rapid and massive myonuclear accretion (20% increase after 48&#x000a0;h), which is dependent upon calcineurin/nuclear factor of activated T cells signalling pathway. In vivo bromodeoxyuridine labelling and proliferating cell nuclear antigen immunodetection revealed that PPAR&#x003b2; activation did not promote cell proliferation, suggesting that the PPAR&#x003b2;-promoted myonuclear accretion involves fusion of pre-existing muscle precursor cells to myofibres rather than cell division. Finally, we showed that in skeletal muscle, ageing led to a down-regulation of PPAR&#x003b2; accompanied by decrease of both oxidative fibre number and myonuclear density. PPAR&#x003b2; pharmacological activation counteracts, at least in part, the ageing-driven muscle remodelling.</p></abstract><kwd-group><title>Keywords</title><kwd>Skeletal muscle fibre</kwd><kwd>Myoblasts</kwd><kwd>Myogenic response</kwd><kwd>Muscle plasticity</kwd><kwd>Calcineurin</kwd></kwd-group><custom-meta-wrap><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer-Verlag 2009</meta-value></custom-meta></custom-meta-wrap></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p>Adult skeletal muscle displays a remarkable capacity for regeneration and adaptation. Skeletal myofibres represent the largest cells in the body. They are syncitial, post-mitotic and terminally differentiated [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR37">37</xref>]. Muscle fibres are unable to proliferate but contain a pool of muscle precursor cells (MPCs), commonly called &#x0201c;satellite cells&#x0201d;, which reside between the basal lamina and the sarcolemma [<xref ref-type="bibr" rid="CR19">19</xref>]. The term of muscle precursor cells is used in this report due to the heterogeneity within the satellite cell population [<xref ref-type="bibr" rid="CR40">40</xref>].</p><p>MPCs play crucial roles in muscle physiology, particularly in muscle repair and regeneration. In response to stress-induced myofibre damages, reparation results from the fusion of MPCs with damaged but viable myofibres [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR28">28</xref>] and regeneration from the fusion of several MPCs within the basal lamina of the destroyed fibres for de novo myofibre formation [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR44">44</xref>]. MPCs proliferation is a preliminary and obligatory step of these processes [<xref ref-type="bibr" rid="CR26">26</xref>].</p><p>MPCs are also involved in adaptive response of skeletal muscle to acute and chronic changes in intensity or type of physical activity, such as muscle functional overload, treadmill running, chronic motor nerve stimulation or voluntary running [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR32">32</xref>]. In these particular conditions, MPCs proliferation is required for modifications of myonuclear density and myofibre hypertrophy but does not seem to be necessary for fibre twitch from faster to slower phenotype [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR29">29</xref>]. However, myonuclear accretion is an early event of the adaptive response to aerobic training which is characterised by a transition from glycolytic to oxidative fibres. Furthermore, Tseng et al. showed that slow fibres always had small volume/myonucleus regarding to fibre diameter and that fast/oxidative fibres with high succinate dehydrogenase (SDH) activity appeared to have lower volume/myonucleus than fast/glycolytic fibres [<xref ref-type="bibr" rid="CR39">39</xref>]. These differences in nuclear domain size between fibre types were proposed to be related to the greater amount of proteins required for oxidative metabolism, including those implicated in mitochondrial structure and functions.</p><p>Finally, the role of MPCs in age-related muscle atrophy is poorly documented, and conflicting observations have been reported. It seems that ageing does not affect the ability of MPCs to respond to various challenges even if there might exist a delay in the proliferative responses of MPCs from aged muscle [<xref ref-type="bibr" rid="CR12">12</xref>]. Brack et al. reported that in large fast muscle fibres, the decrease of myonuclei per muscle unit preceded muscle atrophy. Authors proposed that the age-related decrease in myofibre size may actually be a compensatory response to an inadequate capacity for myonuclear replacement [<xref ref-type="bibr" rid="CR4">4</xref>]. Bruusgaard et al. reported that aged mice display a reduction of muscle size as well as a reduction in myonuclear number [<xref ref-type="bibr" rid="CR5">5</xref>]. In aged mouse muscles, authors have visualised many fragmented nuclei suggesting increased apoptosis and have proposed that reduction of myonuclei in old muscle could result in a reduction of regenerative capacity of MPCs [<xref ref-type="bibr" rid="CR5">5</xref>]. This hypothesis is in contrast with previous observations made in muscle inactivity experiments, in which fibre size reduction precedes the decrease in myonuclei number [<xref ref-type="bibr" rid="CR45">45</xref>].</p><p>We previously described the effect of peroxisome proliferator-activated receptor (PPAR&#x003b2;) over-expression or pharmacological activation in mouse tibialis anterior (TLA), a fast/oxidative-glycolytic muscle [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR17">17</xref>]. In both models, we reported an impressive muscle remodelling characterised by 37% hyperplasia and an increase in oxidative fibre and capillary number [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR18">18</xref>]. In PPAR&#x003b2; agonist-treated animals, this remodelling takes place within only 2&#x000a0;days [<xref ref-type="bibr" rid="CR10">10</xref>]. Because of the observed oxidative and angiogenic remodelling as well as the improvement of metabolic profiles of PPAR&#x003b2; agonist-treated animals and humans [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR41">41</xref>], it was proposed that activation of the PPAR&#x003b2; pathway mimics, at least partially, the adaptive response of muscle to aerobic training. Muscle hyperplasia is indicative of MPC activation [<xref ref-type="bibr" rid="CR14">14</xref>]. Furthermore, we have actually reported an increase of Myf5 and MyoD1 proteins immediately after pharmacological PPAR&#x003b2; activation using GW0742, also suggesting the possible activation of MPCs [<xref ref-type="bibr" rid="CR10">10</xref>].</p><p>As physical exercise and ageing are two physiological situations affecting myonuclear densities, we asked how PPAR&#x003b2; over-expression or pharmacological activation affects myonuclear number in the TLA muscle from young and aged mice. Furthermore, we investigated whether or not MPC proliferation was required. We report here a new striking phenotype for both PPAR&#x003b2; over-expressing and PPAR&#x003b2; agonist-treated mice. In both cases, the number of nuclei per unit of fibre length is significantly increased. This augmentation of myonuclear density follows the same kinetic as the previously described muscle oxidative and angiogenic remodelling induced by PPAR&#x003b2; pharmacological activation, starting at day 1 and being completed at day 2 of treatment [<xref ref-type="bibr" rid="CR10">10</xref>]. Interestingly, myonuclear accretion does not require cell proliferation. As previously described for other PPAR&#x003b2;-dependent remodelling [<xref ref-type="bibr" rid="CR10">10</xref>], the increase in myonuclear density is prevented by inhibition of the calcineurin pathway. Finally, we show that PPAR&#x003b2; is down-regulated in aged mouse muscles and that pharmacological PPAR&#x003b2; activation, using GW0742, restores in large part the age-related loss of myonuclei.</p></sec><sec id="Sec9" sec-type="materials|methods"><title>Materials and methods</title><sec id="Sec10"><title>Animals</title><p>Animals were maintained in a 12/12&#x000a0;h lighting cycle and received food (UAR, France) and water ad libitum. All experimental procedures were conducted according to French legislation. Ten-week-old male C57BL6J (Janvier, France) and 10&#x000a0;weeks and 19&#x000a0;month-old male B6D2 (maintained in our animal facility) were used in the various experiments. We always used four animals per condition to obtain statistical values. Animals were killed after the indicated times by cervical dislocation, and tibialis anterior muscles were harvested immediately after killing.</p><p>Animals over-expressing PPAR&#x003b2; specifically in skeletal muscle were generated as previously described [<xref ref-type="bibr" rid="CR18">18</xref>]. Briefly, B6D2 mice harbouring a loxP&#x02013;stop&#x02013;loxP&#x02013;PPAR&#x003b2;&#x02013;hygromycine construction were crossed with B6D2 mice expressing Cre recombinase under human skeletal actin (HSA) promoter [<xref ref-type="bibr" rid="CR20">20</xref>]. All animals were maintained hemizygous for their transgene. Presence of the transgenes was verified by polymerase chain reaction (PCR) analyses of tail DNA (REDExtract-N-Amp Tissue PCR Kit, Sigma). Animals harbouring the two transgenes were used as PPAR&#x003b2;-overexpressing mice, while animals harbouring the HSA-Cre transgene only were used as control.</p></sec><sec id="Sec11"><title>Injections</title><p>GW0742, a PPAR&#x003b2;-specific activator [<xref ref-type="bibr" rid="CR38">38</xref>], was dissolved in Dulbecco&#x02019;s modified Eagle&#x02019;s medium/dimethyl sulphoxide (DMSO) 6% (Gibco) and injected subcutaneously once a day (9&#x000a0;<sc>a.m</sc>.) at 1&#x000a0;mg/kg. Control animals received vehicle at 9&#x000a0;<sc>a.m</sc>..</p><p>Cyclosporine A (Sigma) treatments were performed twice a day (9&#x000a0;<sc>a.m</sc>. and 6&#x000a0;<sc>p.m</sc>.) by subcutaneous injections at 25&#x000a0;mg/kg in DMSO. In these experiments, GW0742 was injected subcutaneously once a day (2&#x000a0;<sc>p.m</sc>.) at 1&#x000a0;mg/kg. Injections of vehicle were performed at 9&#x000a0;<sc>a.m</sc>., 2&#x000a0;<sc>p.m</sc>. and 6&#x000a0;<sc>p.m</sc>. (Control group), 9&#x000a0;<sc>a.m</sc>. and 6&#x000a0;<sc>p.m</sc>. (GW group) and 2&#x000a0;<sc>p.m</sc>. (CsA group).</p><p>BrdU (Sigma) treatments were performed once a day (9&#x000a0;<sc>a.m</sc>.) by intra-peritoneal injections of the compound at 100&#x000a0;mg/kg in 0.9% NaCl. In these experiments, GW0742 was injected subcutaneously once a day (2&#x000a0;<sc>p.m</sc>.) at 1&#x000a0;mg/kg. Injections of vehicle were performed at 9&#x000a0;<sc>a.m</sc>. and 2&#x000a0;<sc>p.m</sc>. in control groups.</p></sec><sec id="Sec12"><title>Immunofluorescence analysis</title><p>Tibialis anterior (TLA) muscles and duodenum were harvested and frozen in tissue embedding medium (VWR International) immediately after mice were killed. Ten-micrometre cryosections were performed from the middle part of muscle or from duodenum, placed on poly-lysine coated slides (VWR International) and processed for immunofluorescence analyses. Mouse monoclonal NFATc1 (7A6, sc-7294, Santa Cruz Biotechnology) and goat anti-mouse fluorescein conjugate antibodies were both used at 1:200 dilution. For BrdU immunofluorescence, cryosections were fixed on slide according manufacturer&#x02019;s protocol and then incubated 45&#x000a0;min with an anti-BrdU antibody (Anti-Bromodeoxyuridine-Fluorescein, Roche). Finally, slides were mounted with Vectashield containing DAPI (H-1200, Vector laboratories, Burlingame, CA, USA). Slides were viewed under an epifluorescence microscope connected to a digital camera with the Spot software (Universal Imaging).</p></sec><sec id="Sec13"><title>Histological and immunohistochemical analysis</title><p>TLA muscles and duodenum were harvested, fixed in 4% paraformaldehyde (PFA) overnight, dehydrated and then embedded in paraffin. Paraffin sections (5&#x000a0;&#x003bc;m) were used for either BrdU or PCNA antigen detection using M.O.M. Kit (PK-2200, Vector Laboratories). BrdU (11170376001, Roche), PCNA (PC10, Sc-56, Santa Cruz Biotechnology) and mouse monoclonal antibodies were used in a 1:50 and 1:100 dilution, respectively. DAB (SK-4100, Vector Laboratories) served as a substrate. Nuclei were counterstained with haematoxylin. Slides were viewed under an epifluorescence microscope connected to a digital camera with the Spot software (Universal Imaging).</p></sec><sec id="Sec14"><title>Single-fibre isolation</title><p>Single fibres were isolated. Both fibre length and myonuclear number were assessed as described by Brack et al. [<xref ref-type="bibr" rid="CR4">4</xref>]. Briefly, TLA muscles were fixed in 4% PFA during 2&#x000a0;days at room temperature. Muscles were then treated 2&#x000a0;h in 40% NaOH (<italic>w</italic>/<italic>v</italic>) and agitated vigorously for 10&#x000a0;min. Released fibres were washed in phosphate-buffered saline (PBS; pH 7.4) and stored at 4&#x000b0;C in PBS 0.05% azide.</p></sec><sec id="Sec15"><title>Myonuclear density analysis</title><p>After DAPI staining, images of 40 single isolated fibres per animal (four animals per group) were captured using a Z-stacking procedure on a Zeiss Apotome (&#x000d7;10 objective), then Z-projected using the open source ImageJ software (Wayne Rasband, National institutes for Health). Fibre diameters were measured at six locations over at least 500&#x000a0;&#x003bc;m length of the fibre, and all nuclei were counted using Olympus DP-Soft software. Values obtained were averaged to obtain mean value per fibre. Any damaged areas of the fibres were not analysed.</p></sec><sec id="Sec16"><title>Sodium dodecyl sulfate polyacrylamide gel electrophoresis and Western blot</title><p>Total TLA lysates from the mice treated with GW0742 or vehicle alone (DMSO) were prepared, electrophoresed and blotted on polyvinylidene difluoride membrane. Subcellular fractionation of TLA muscles was performed using the Qproteome&#x02122; Cell Compartment Kit (Quiagen) according to manufacturer&#x02019;s instructions. The following antibodies were used at the indicated dilutions for immunodetection: Pan A calcineurin (AB1695, Chemicon International) 1:1,000, polyclonal anti P85 (PI3K subunit) from rabbit (06-496, Upstate, Lake Placid, NY, USA) 1:1,000, polyclonal anti CREB from rabbit (kind gift of Dr. M. Montminy, San Diego, USA) 1:2,000, polyclonal anti Rho GDIa from rabbit (A-20, sc-360, Santa Cruz Biotechnology) 1:500, polyclonal anti acetyl-histone 3 from rabbit (06-599, Upstate, Lake Placid, NY,USA) 1:1,000, monoclonal NFATc1 from mouse (7A6, sc-7294, Santa Cruz Biotechnology) 1:200, monoclonal NFATc3 from mouse (F-1, sc-8405, Santa Cruz Biotechnology) 1:200, peroxidase-coupled anti-rabbit and peroxidase-coupled anti-mouse secondary antibodies (Vector Laboratories) 1:5,000.</p></sec><sec id="Sec17"><title>Quantitative reverse transcription PCR</title><p>Reverse transcription was performed using 0.2&#x000a0;&#x003bc;g of total RNA from muscle of 10&#x000a0;week-old and 19&#x000a0;month-old C57Bl6 mice (five animals per group), a Core kit (RT-RTCK-03, Eurogentec) according to manufacturer&#x02019;s instruction and a mix of random primers (9 mers) and oligodT. qPCR was performed on SDS7900HT (Applied Biosystem) using Mesagreen qPCR kit for SYBR (Eurogentec) and the following primers: <list list-type="bullet"><list-item><p>PPAR&#x003b2;: 5&#x02032;-AGATGGTGGCAGAGCTATGACC-3&#x02032;; 5&#x02032;-TCCTCCTGTGGCTGTTCC-3&#x02032;.</p></list-item><list-item><p>Catalase: 5&#x02032;-GGATCCTGACATGGTCTGGG-3&#x02032;; 5&#x02032;-TGGAGAGACTCGGGACGAAG-3&#x02032;.</p></list-item><list-item><p>PDK4: 5&#x02032;-GCATTTCTACTCGGATGCTCAATG-3&#x02032;; 5&#x02032;-CCAATGTGGCTTGGGTTTCC-3&#x02032;.</p></list-item><list-item><p>36B4: 5&#x02032;-TCCAGGCTTTGGGCATCA-3&#x02032;; 5&#x02032;-CTTTATCAGCTGCACATCACTCAGA-3&#x02032;.</p></list-item></list></p><p>Data were all normalised using 36B4 as housekeeping gene.</p></sec><sec id="Sec18"><title>Statistical analysis</title><p>The effect of the duration of treatment was performed by a one-way analysis of variance (ANOVA) test. Two-way ANOVA tests were performed for comparisons between groups (age and treatment; age and transgenicity). When significant changes were observed in ANOVA tests, Fisher&#x02019;s protected least significant difference post hoc test was applied to locate the source of significant differences. When two groups were compared, we used a Student&#x02019;s <italic>t</italic> test. Analyses were performed with Stat&#x02019;View Abacus Concept version 5. Hierarchical ascendant classifications were performed for the determination of fibre groups according to nuclei/mm of fibre length. Results are presented as means&#x02009;&#x000b1;&#x02009;SD with significance accepted when <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05.</p></sec></sec><sec id="Sec2" sec-type="results"><title>Results</title><sec id="Sec3"><title>PPAR&#x003b2; pathway activation promotes an increase in myonuclear density in TLA muscle</title><p>The effects of PPAR&#x003b2; over-expression on myonuclear density were first investigated by quantification of myonuclear number per millimetre of fibre length in diamidino-2-phenyl-indole (DAPI)-stained isolated fibres, prepared from TLA muscle of adult B6D2 PPAR&#x003b2; transgenic mice and control littermates (Tg and Ct; Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>a). These experiments revealed that muscle-specific PPAR&#x003b2; over-expression leads to a 14% increase of nuclei number per millimetre of fibre length (92&#x02009;&#x000b1;&#x02009;1.32, <italic>n</italic>&#x02009;=&#x02009;160 fibres for controls versus 105&#x02009;&#x000b1;&#x02009;3.2, <italic>n</italic>&#x02009;=&#x02009;160 fibres for PPAR&#x003b2; transgenic mice, <italic>p</italic>&#x02009;=&#x02009;0.003). Using ascendant hierarchical classification, we defined three groups of myofibres, i.e. those containing less than 85 nuclei/mm (<italic>F</italic>&#x02009;&#x0003c;&#x02009;85), those containing a number of nuclei comprised between 85 and 100 nuclei/mm (85&#x02009;&#x0003c;&#x02009;<italic>F</italic>&#x02009;&#x0003c;&#x02009;100) and those containing more than 100 nuclei/mm (<italic>F</italic>&#x02009;&#x0003e;&#x02009;100). As shown in Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>b, PPAR&#x003b2; over-expression induced major changes in myofibre distribution in these three groups with reduction of myofibre numbers in both the <italic>F</italic>&#x02009;&#x0003c;&#x02009;85 (31% to 10%) and 85&#x02009;&#x0003c;&#x02009;<italic>F</italic>&#x02009;&#x0003c;&#x02009;100 (41% to 35%) groups, while the number of fibres in the <italic>F</italic>&#x02009;&#x0003e;&#x02009;100 group is notably increased (28% to 55%). <fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Muscle-specific PPAR&#x003b2; over-expression promotes an increase of myonuclear density. <bold>a</bold> Representative isolated DAPI-stained fibres harvested from tibialis anterior of 10-week-old control (<italic>Ct</italic>) and PPAR&#x003b2; transgenic (<italic>Tg</italic>) B6D2 mice. Global myonuclear density is indicated as myonuclei number per millimetre of fibre length (<italic>n</italic>&#x02009;=&#x02009;160, four animals per group, 40 fibres per animal). <bold>b</bold> Distribution of myofibres population in TLA from control and PPAR&#x003b2; overexpressing mice. Myonuclei in isolated DAPI-stained fibres (<italic>n</italic>&#x02009;=&#x02009;160, four animals per group, 40 fibres per animal) harvested from tibialis anterior of 10-week-old control (<italic>Ct</italic>) and PPAR&#x003b2; transgenic (<italic>Tg</italic>) B6D2F1 mice were quantified and pooled using ascendant hierarchical classification in three groups of fibres containing (1) less than 85 nuclei, (2) from 85 to 100 nuclei and (3) more than 100 nuclei/mm of fibre length. Percentage of each group, mean number of nuclei in each group (<italic>Mean</italic>) and standard deviation (<italic>s.d.</italic>) are reported for control (<italic>Ct</italic>) and PPAR&#x003b2; transgenic (<italic>Tg</italic>) mice</p></caption><graphic position="anchor" xlink:href="424_2009_676_Fig1_HTML" id="MO1"/></fig></p><p>We then investigated the effects of pharmacological PPAR&#x003b2; activation on myonuclear density by treating 10-week-old C57Bl6 male mice with GW0742, a PPAR&#x003b2;-specific agonist [<xref ref-type="bibr" rid="CR38">38</xref>]. The number of myonuclei/mm fibre length was determined at increasing times after GW0742 or vehicle injections. We first noticed a significant strain difference concerning the myonuclear density (92&#x02009;&#x000b1;&#x02009;1.32 and 86&#x02009;&#x000b1;&#x02009;1.40, in B6D2 and C57Bl6 mice, respectively) as well as the distribution in the three predefined groups between B6D2 and C57Bl6 mice (compare Ct in Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>b to Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>b). As expected, vehicle treatment did not affect myonuclear density nor distribution in the three predefined groups of fibres (not shown). On the contrary, PPAR&#x003b2; activation promoted a fast increase in myonuclear density with an 11% (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001) increase after 1&#x000a0;day and a maximal augmentation of 20% (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001) reached after 2&#x000a0;days of treatment (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>a). Classification of fibres in the three predefined groups revealed that, as previously observed in PPAR&#x003b2; transgenic mice, pharmacological PPAR&#x003b2; activation resulted in time-dependent and notable changes in fibre group distribution in favour of fibres with a high myonuclear density. This shift towards the <italic>F</italic>&#x02009;&#x0003e;&#x02009;100 group is progressive from 8% to 34% after 1&#x000a0;day and to a maximum of 62% reached after 2&#x000a0;days, with a parallel decrease of percentage of fibres in both <italic>F</italic>&#x02009;&#x0003c;&#x02009;85 group (47% to 28% after 1&#x000a0;day and to 15% after 2&#x000a0;days) and 85&#x02009;&#x0003c;&#x02009;<italic>F</italic>&#x02009;&#x0003c;&#x02009;100 group (45% to 38% after 1&#x000a0;day and to 23% after 2&#x000a0;days; Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>b). <fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>PPAR&#x003b2; pharmacological activation induces an increase of myonuclear density. <bold>a</bold> Quantification of myonuclei number in isolated DAPI-stained fibres (<italic>n</italic>&#x02009;=&#x02009;160, four animals per group, 40 fibres per animal) harvested from tibialis anterior of 10-week-old C57Bl6 mice for different times of treatment with vehicle (<italic>Ct</italic>) or PPAR&#x003b2; agonist GW0742 (1&#x000a0;day (<italic>1d</italic>), 2&#x000a0;days (<italic>2d</italic>) and 4&#x000a0;days (<italic>4d</italic>)). *<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001, different from vehicle-treated group (<italic>Ct</italic>); <italic>pound sign p</italic>&#x02009;&#x0003c;&#x02009;0.01, different from 1&#x000a0;day treated animal group (<italic>1d</italic>). <bold>b</bold> Distribution of myofibres population counted in <bold>a</bold> using the same classification as in Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1b</xref>. Percentage of each group, mean number of nuclei in each group (<italic>Mean</italic>) and standard deviation (<italic>s.d.</italic>) are reported for each period of treatment with GW0742</p></caption><graphic position="anchor" xlink:href="424_2009_676_Fig2_HTML" id="MO2"/></fig></p></sec><sec id="Sec4"><title>Pharmacological PPAR&#x003b2; activation does not promote cell division in TLA muscle</title><p>The fast and important increase in myonuclear density as well as hyperplasia suggests major events of MPC activation and fusion to myofibres. However, the quickness of myonuclear accretion in response to PPAR&#x003b2; activation argues against a process requiring cell proliferation. To investigate directly the effect of PPAR&#x003b2; activation on cell proliferation in TLA muscle, we explored by immunochemistry the expression of a well-known mitosis marker, the proliferating cell nuclear antigen (PCNA), in muscles from animals receiving or not GW0742 for various times. Sections of the duodenum from control animals were used as positive control and displayed, as expected, an important labelling in the crypts (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>a). In contrast, nearly no PCNA-positive myonuclei were detectable in sections from control animals (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>b). As shown in Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>, PPAR&#x003b2; activation did not increase the number of PCNA-positive myonuclei, whatever the period of treatment with GW0742 was, i.e. 5&#x000a0;h (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>c), 24&#x000a0;h (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>d), or 48&#x000a0;h (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>e, f). However, after 48&#x000a0;h of PPAR&#x003b2; agonist treatment, several fibres with centrally located myonuclei can be observed as a mark of myonuclear accretion (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>e and f). These results suggest that PPAR&#x003b2;-promoted myonuclear accretion did not involve proliferation of MPCs. Finally, we did detect some PCNA-positive cells but almost only in blood vessels (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>d, h&#x02013;j at high magnification). <fig id="Fig3"><label>Fig.&#x000a0;3</label><caption><p>GW0742-promoted myonuclear remodelling is independent of cell proliferation in tibialis anterior. Immunohistochemical localization of PCNA, a well-known mitotic marker, in <bold>a</bold> section of duodenum as positive control, <bold>b</bold>, <bold>g</bold> section of TLA muscles from vehicle-treated animals, <bold>c</bold>&#x02013;<bold>j</bold> sections of TLA muscles from animals receiving GW0742 for various times: <bold>c</bold>, <bold>h</bold> 5&#x000a0;h, <bold>d</bold>, <bold>i</bold> 24&#x000a0;h, <bold>e</bold>, <bold>f</bold>, <bold>j</bold> 48&#x000a0;h. Note the important labelling in the crypts and the quasi absence of positive myonuclei in both control and GW0742-treated animals. PCNA signals were often detected in blood vessels (<italic>arrows</italic> in <bold>d</bold>, <bold>h</bold>&#x02013;<bold>j</bold>) but rarely in myonuclei (arrows in <bold>c</bold>). Finally, note the elevated number of centrally located nuclei (<italic>arrowhead</italic> in <bold>e</bold>, <bold>f</bold>). Scale bars, 50&#x000a0;&#x003bc;m</p></caption><graphic position="anchor" xlink:href="424_2009_676_Fig3_HTML" id="MO3"/></fig></p><p>To confirm these observations, bromodeoxyuridine (BrdU) incorporation into DNA was used. In vivo BrdU labelling technique allows identification of MPCs that have proliferated, migrated and either incorporated into existing myofibres or having been implicated in the formation of new fibres [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR35">35</xref>]. BrdU incorporation into DNA was determined by two different methods, indirect immunofluorescence on cryosections and immunochemistry on paraffin-embedded sections. As shown in Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>a, b, sections from the duodenum of control animals that received for 1 (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>b) or 2&#x000a0;days (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>a) daily injections of BrdU validated the method to follow cell proliferation in vivo, as BrdU-positive cells are detected both in crypts, where the cells are proliferating, and in the lower parts of the villi that contain epithelial cells, which have proliferated in the crypts (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>b) and then migrated during their differentiation towards the villous apex (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>a). Data presented in Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref> confirmed that PPAR&#x003b2;-promoted muscle remodelling does not implicate cell proliferation as the number of BrdU-positive nuclei remained very low in muscle from animals treated for 2&#x000a0;days with GW0742. Less than 1% of nuclei were BrdU-positive, and no significant difference was found compared to muscles from untreated animals. Furthermore, as previously observed, several myofibres containing central nuclei can be evidenced in muscles from animals treated for 48&#x000a0;h with GW0742 (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>c, e, f). Interestingly, these nuclei remained BrdU-negative. As central nuclei are marks of the fusion of MPCs to fibres and/or newly formed myofibres, these observations also strongly support the conclusion that myonuclear accretion and fibre hyperplasia promoted by PPAR&#x003b2; activation took place without MPC proliferation. <fig id="Fig4"><label>Fig.&#x000a0;4</label><caption><p>GW0742-promoted myonuclear remodelling does not require cell division in tibialis anterior. Mice were injected with BrdU and or not with GW0742. Duodenum (<bold>a</bold>, <bold>b</bold>) or TLA muscle (<bold>c</bold>&#x02013;<bold>f</bold>) harvested from 24&#x000a0;h (<bold>b</bold>) or 48&#x000a0;h (<bold>a</bold>, <bold>c</bold>&#x02013;<bold>f</bold>) post GW0742 treatment, were either frozen in tissue-embedding medium or fixed, dehydrated and embedded in paraffin. Frozen sections on slides were stained with anti-BrdU antibody coupled to fluorescein (<bold>a</bold>, <bold>c</bold>, <bold>e</bold>) and mounted using Vectashield containing DAPI as described in &#x0201c;<xref rid="Sec9" ref-type="sec">Materials and methods</xref>&#x0201d;. Positive cells are detected in blood vessels, and very few myonuclei are labelled (<bold>c</bold>, <bold>e</bold>). <italic>Arrowheads</italic> indicate myofibres with central nucleus (<bold>c</bold>, <bold>e</bold>). Paraffin sections were stained with anti-BrdU antibody (<bold>b</bold>, <bold>d</bold>, <bold>f</bold>) as described in &#x0201c;<xref rid="Sec9" ref-type="sec">Materials and methods</xref>&#x0201d;, and nuclei were counterstained with haematoxylin. Very few myonuclei are labelled (<bold>d</bold>, and arrow in <bold>f</bold>); on the contrary, a large number of myofibres with one or more central nuclei are visible (<bold>d</bold>, <bold>e</bold>, <bold>f</bold>). Note the increased BrdU labelling in the duodenum sections between 24&#x000a0;h (<bold>b</bold>) and 48&#x000a0;h (<bold>a</bold>) of the BrdU pulse. Scale bar, 50&#x000a0;&#x003bc;m</p></caption><graphic position="anchor" xlink:href="424_2009_676_Fig4_HTML" id="MO4"/></fig></p></sec><sec id="Sec5"><title>Positive effects of PPAR&#x003b2; activation on myonuclear density are dependent of the calcineurin/NFAT pathway</title><p>We previously provided evidences that the active calcineurin pathway is required for the myogenic and angiogenic responses to PPAR&#x003b2; activation in the adult mouse [<xref ref-type="bibr" rid="CR10">10</xref>]. To test whether an active calcineurin pathway was required for the PPAR&#x003b2;-promoted myonuclear accretion, we explored the effects of co-administration of cyclosporine A (CsA), a potent inhibitor of calcineurin/nuclear factor of activated T-cells (NFAT) pathway, on TLA myonuclear density in mice treated by GW0742 for 2&#x000a0;days.</p><p>As shown in Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>a, b, CsA administration alone neither affected the myonuclear density nor the distribution in the three defined fibre groups. On the contrary, CsA administration totally blunted the PPAR&#x003b2;-dependant increment of global myonuclear density (from 86 to 104 nuclei/mm in the absence and to 87 nuclei/mm in presence of CsA; Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>a). Calcineurin inhibition strongly reduced the redistribution of myofibres towards the group with the highest myonuclear density (shift from 8% to 62% in the absence of CsA versus shift from 8% to 20% when CsA was co-administrated; Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>b). <fig id="Fig5"><label>Fig.&#x000a0;5</label><caption><p>Positive effects of PPAR&#x003b2; on myonuclear density are calcineurin dependent. <bold>a</bold> Quantification of nuclei number in isolated DAPI-stained fibres harvested from tibialis anterior of 10-week-old C57Bl6 animals (<italic>n</italic>&#x02009;=&#x02009;160, four animals per group, 40 fibres per animal), treated 2&#x000a0;days with vehicle (<italic>Ct</italic>), cyclosporine A (<italic>CsA</italic>), PPAR&#x003b2; agonist GW0742 (<italic>2d</italic>) or PPAR&#x003b2; agonist GW0742 and cyclosporine A (<italic>2d&#x02009;+&#x02009;CsA</italic>). *<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01, different from Ct, CsA and 2d&#x02009;+&#x02009;CsA groups. <bold>b</bold> Distribution of myofibres population counted in <bold>a</bold> using the same classification as in Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1b</xref>. Percentage of each group, mean number of nuclei in each group (<italic>Mean</italic>) and standard deviation (<italic>s.d.</italic>) are reported for each treatment</p></caption><graphic position="anchor" xlink:href="424_2009_676_Fig5_HTML" id="MO5"/></fig></p><p>Our data also indicated that in TLA muscle, GW0742 treatment did not promote an increase of calcineurin at the protein level (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>a) but rather provokes an induction of its phosphatase activity as attested by the rapid nuclear translocation of nuclear factor of activated T cells C1 and C3. Indeed, enhanced NFATc1 nuclearization can be evidenced as soon as 5&#x000a0;h after GW0742 treatment (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>b, c). It remained high at 24&#x000a0;h of treatment and returned to control value after 48&#x000a0;h (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>c). NFATc3 nuclearization can be evidenced after 24&#x000a0;h of PPAR&#x003b2; agonist treatment, and it returned to control values after 48&#x000a0;h of treatment. <fig id="Fig6"><label>Fig.&#x000a0;6</label><caption><p>GW0742 induces calcineurin A-dependent NFAT nuclearization. <bold>a</bold> Calcineurin and P85 Western blot analysis after control treatment (<italic>DMSO 5H</italic>) or different times of GW0742 treatment (2, 5, 8, and 24&#x000a0;h). P85 is used as loading control. <bold>b</bold> Immunohistochemical localization of NFATc1 using cryosections of TLA muscles from mice treated 5&#x000a0;h with DMSO (<italic>DMSO 5H</italic>), GW0742 (<italic>GW 5H</italic>) or cyclosporine A and GW0742 (<italic>CsA&#x02009;+&#x02009;GW 5H</italic>). Note the increased NFATc1 nuclearization only in GW 5H-treated animals. <bold>c</bold> TLA muscles from mice treated 5 or 24&#x000a0;h with DMSO (<italic>DMSO 5h</italic>, <italic>DMSO 24h</italic>), or treated 5, 24, or 48&#x000a0;h with GW0742 (<italic>GW 5h</italic>, <italic>GW 24h</italic>, <italic>GW 48h</italic>) were used for subcellular fractionation in cytoplasmic (<italic>C</italic>), nuclear (<italic>N</italic>) and insoluble-chromatin-associated (<italic>I</italic>) proteins and subsequent Western blot analysis. Note the increased nuclear localization of NFATc1 and NFATc3 in response to PPAR&#x003b2; activation. CREB (nuclear), Rho GDI&#x003b1; (cytoplasmic) and acetylated histone H3 (H3, Chromatin associated) antibodies were used to evaluate the purity of each fraction. Scale bar, 50&#x000a0;&#x003bc;m</p></caption><graphic position="anchor" xlink:href="424_2009_676_Fig6_HTML" id="MO6"/></fig></p></sec><sec id="Sec6"><title>Ageing promotes a decrease in myonuclear density, while PPAR&#x003b2; agonist treatment restores a juvenile phenotype</title><p>Myonuclear density is negatively regulated by ageing [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>]. In order to explore a possible role of PPAR&#x003b2; in this a process, we first investigated the effect of ageing on PPAR&#x003b2; expression by comparing the amounts of the corresponding mRNA in mouse TLA from adult (10-week-old) and aged (19-month-old) mice. As shown in Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7</xref>, PPAR&#x003b2; mRNA was down-regulated by more than 30% (<italic>p</italic>&#x02009;=&#x02009;0.03, <italic>n</italic>&#x02009;=&#x02009;5) in aged mouse muscles when compared to young mouse muscles. To check whether the decreased expression of PPAR&#x003b2; impacts on gene regulation, we also quantified mRNA for two PPAR&#x003b2;-target genes, namely catalase, that plays a crucial role in the protection against oxidative stress [<xref ref-type="bibr" rid="CR23">23</xref>], and pyruvate dehydrogenase kinase 4 (PDK4) that is involved in metabolic regulations [<xref ref-type="bibr" rid="CR7">7</xref>]. These experiments revealed that in aged mice, both genes were down-regulated (40%, <italic>p</italic>&#x02009;=&#x02009;0.01, and 75%, <italic>p</italic>&#x02009;=&#x02009;0.001 for catalase and PDK4, respectively; Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7</xref>a). However, PPAR&#x003b2; pathway remains active in aged mice as 4&#x000a0;days of GW0742 treatment promoted an up-regulation of these target genes (1.76-fold, <italic>p</italic>&#x02009;=&#x02009;0.034, and 6.19-fold, <italic>p</italic>&#x02009;=&#x02009;0.047 for catalase and PDK4, respectively; Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7</xref>b). As expected, GW0742 treatment did not modify PPAR&#x003b2; expression. <fig id="Fig7"><label>Fig.&#x000a0;7</label><caption><p>Ageing reduces expression of PPAR&#x003b2;, catalase and PDK4 mRNAs. <bold>a</bold> Quantification of PPAR&#x003b2;, catalase and PDK4 using mRNAs from muscles of 10-week-old (<italic>white bar</italic>) and 19-month-old (<italic>dark bar</italic>) mice (five animals per group) and qPCR analyses as described in &#x0201c;<xref rid="Sec9" ref-type="sec">Materials and methods</xref>&#x0201d;. *<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05, different from 10-week-old mice group; <italic>pound sign p</italic>&#x02009;&#x0003c;&#x02009;0.005, different from 10-week-old mice group. <bold>b</bold> Quantification of PPAR&#x003b2;, catalase and PDK4 using mRNAs from muscles of 20-month-old mice treated (<italic>cross-hatched bar</italic>) or not (<italic>dark bar</italic>) during 4&#x000a0;days with GW0742 (four animals per group) and qPCR analyses as described in &#x0201c;<xref rid="Sec9" ref-type="sec">Materials and methods</xref>&#x0201d;. *<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05, different from 20-month-old untreated mice group. Results in <bold>a</bold> and <bold>b</bold> were normalised using 36B4 as housekeeping gene</p></caption><graphic position="anchor" xlink:href="424_2009_676_Fig7_HTML" id="MO7"/></fig></p><p>The effect of ageing on myonuclear density was next investigated in TLA muscles from young and aged B6D2 control mice (Ct and 19Ct in Fig.&#x000a0;<xref rid="Fig8" ref-type="fig">8</xref>a, b). As shown in Fig.&#x000a0;<xref rid="Fig8" ref-type="fig">8</xref>a and in agreement with other reports [<xref ref-type="bibr" rid="CR5">5</xref>], global myonuclear density was slightly but significantly lower in aged mice when compared to young adult animals (&#x02212;5%, <italic>p</italic>&#x02009;=&#x02009;0.0057). The effect of ageing on myonuclear density is further evidenced when evaluating the fibre distribution profile in the previously defined groups. In aged mice, the number of fibres in the <italic>F</italic>&#x02009;&#x0003c;&#x02009;85 group was increased by 1.35-fold (31% to 42%), whereas the fibre numbers in <italic>F</italic>&#x02009;&#x0003e;&#x02009;100 and 85&#x02009;&#x0003c;&#x02009;<italic>F</italic>&#x02009;&#x0003c;&#x02009;100 groups were reduced 1.22- and 1.17-fold, respectively compared to those of young mice (Fig.&#x000a0;<xref rid="Fig8" ref-type="fig">8</xref>b). Furthermore, the mean value in the <italic>F</italic>&#x02009;&#x0003c;&#x02009;85 group seems to be lower in aged animals than in young adult animals, whereas other mean values remain stable (Fig.&#x000a0;<xref rid="Fig8" ref-type="fig">8</xref>b). <fig id="Fig8"><label>Fig.&#x000a0;8</label><caption><p>Ageing promotes a 5% decrease of myonuclear density, while PPAR&#x003b2; agonist treatment restores a juvenile phenotype. <bold>a</bold> Quantification of nuclei number in isolated DAPI-stained fibres harvested from tibialis anterior of 10-week-old (<italic>Ct</italic>, <italic>Tg</italic>, <italic>GW</italic>) and 19-month-old (<italic>19Ct</italic>, <italic>19Tg</italic>, <italic>19GW</italic>) B6D2 mice (<italic>n</italic>&#x02009;=&#x02009;160, four animals per group, 40 fibres per animal). Mice were either treated with vehicle only (<italic>Ct</italic>, <italic>19Ct</italic>) or untreated PPAR&#x003b2; transgenic mice (<italic>Tg</italic>, <italic>19Tg</italic>) or treated for 4&#x000a0;days with GW0742 (<italic>GW</italic>, <italic>19GW</italic>). *<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01, different from 10-week-old mice groups (<italic>Ct</italic>, <italic>Tg</italic>, <italic>GW</italic>); <italic>pound sign p</italic>&#x02009;&#x0003c;&#x02009;0.05, different from vehicle-treated groups (<italic>Ct</italic>, <italic>19Ct</italic>). <bold>b</bold> Distribution of myofibres population counted in <bold>a</bold> using the same classification as in Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1b</xref>. Percentage of each group, mean number of nuclei in each group (<italic>Mean</italic>) and standard deviation (<italic>s.d.</italic>) are reported for each experimental condition</p></caption><graphic position="anchor" xlink:href="424_2009_676_Fig8_HTML" id="MO8"/></fig></p><p>To explore a possible beneficial action of PPAR&#x003b2; pathway activation on myonuclear density, we next investigated the effects of muscle specific PPAR&#x003b2; over-expression on the ageing-related loss of myonuclei. In elderly PPAR&#x003b2; transgenic animals, we have observed a significant reduction in global myonuclear density (&#x02212;7%, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0052) and a shift towards fibres that contain fewer nuclei (Tg and 19Tg in Fig.&#x000a0;<xref rid="Fig8" ref-type="fig">8</xref>a, b) when compared to their younger counterparts. Despite this reduction, global myonuclear density in aged transgenic mice remained in the same order of value than that found in young untreated mice (compare CT and 19Tg in Fig.&#x000a0;<xref rid="Fig8" ref-type="fig">8</xref>a). Furthermore, the percentage of fibres in the <italic>F</italic>&#x02009;&#x0003e;&#x02009;100 group remained significantly higher in old transgenic animals than in control young animals (<italic>F</italic>&#x02009;&#x0003e;&#x02009;100&#x02009;=&#x02009;28% and 46% in CT and 19Tg, respectively. Fig.&#x000a0;<xref rid="Fig8" ref-type="fig">8</xref>b). Finally, we studied the effects of pharmacological PPAR&#x003b2; activation on myonuclear density in young and old B6D2F1 mice (GW and 19GW in Fig.&#x000a0;<xref rid="Fig8" ref-type="fig">8</xref>a, b). In young control mice, 4&#x000a0;days treatment with GW0742 resulted in an increase (14%, <italic>p</italic>&#x02009;=&#x02009;0.048) in the global myonuclear density (Fig.&#x000a0;<xref rid="Fig8" ref-type="fig">8</xref>a) and redistribution of fibres in favour of the <italic>F</italic>&#x02009;&#x0003e;&#x02009;100 group (28% to 67%, Fig.&#x000a0;<xref rid="Fig8" ref-type="fig">8</xref>b). This augmentation is similar to that observed in PPAR&#x003b2;-over-expressing transgenic mice (compare CT, TG and GW in Fig.&#x000a0;<xref rid="Fig8" ref-type="fig">8</xref>a) but is less important than the observed 20% increase in young C57Bl6-treated mice (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>a). Interestingly, in aged B6D2F1 mice (19GW), 4&#x000a0;days administration of PPAR&#x003b2; agonist led not only to a 9% (<italic>p</italic>&#x02009;=&#x02009;0.0318) increase in the myonuclear density (compare 19Ct and 19GW in Fig.&#x000a0;<xref rid="Fig8" ref-type="fig">8</xref>a) but also to a redistribution of fibres in the group which contained more than 100 nuclei/mm (<italic>F</italic>&#x02009;&#x0003e;&#x02009;100; 23% to 38%; Fig.&#x000a0;<xref rid="Fig8" ref-type="fig">8</xref>b). The percentage of fibres in the <italic>F</italic>&#x02009;&#x0003c;&#x02009;85 group was reduced (42% to 25%), whereas the 85&#x02009;&#x0003c;&#x02009;<italic>F</italic>&#x02009;&#x0003c;&#x02009;100 group remained stable (Fig.&#x000a0;<xref rid="Fig8" ref-type="fig">8</xref>b). Interestingly, treatment allowed aged mice to reach similar global myonuclear density as 10-week-old control mice (compare 19GW and Ct in Fig.&#x000a0;<xref rid="Fig8" ref-type="fig">8</xref>a), almost the same fibre distribution profile (Fig.&#x000a0;<xref rid="Fig8" ref-type="fig">8</xref>b) and slightly better mean values in the three groups, indicating that PPAR&#x003b2; activation could compensate the age-related loss of myonuclei.</p></sec><sec id="Sec7"><title>Ageing promotes a decrease in oxidative myofibre number, while PPAR&#x003b2; agonist treatment restores a juvenile phenotype</title><p>To characterise the impact of ageing on fibre type composition and the effects of PPAR&#x003b2; activation on this parameter, we used cross-sections around mid-portion of the TLA muscles from 10-week-old and 22-month-old animals treated or not for 4&#x000a0;days with GW0742 for in situ staining of succinate dehydrogenase activity, which is a marker of mitochondrial complex II content. In accordance with our previous observations [<xref ref-type="bibr" rid="CR10">10</xref>], TLA from young adult C57Bl6 mice contains about 46% of SDH-positive fibres and 54% of SDH-negative fibres, and GW0742 treatment promotes an increment of the oxidative phenotype characterised by increased proportion of SDH-positive fibres (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). TLA from aged animals displayed a less oxidative phenotype with decreased proportion of SDH-positive fibres (39.3 % in aged versus 46.3% in young animals). Interestingly, 4&#x000a0;days of GW0742 administration promoted an increase of SDH-positive fibre proportion in aged mouse TLA, resulting in a phenotype that is nearly similar to that observed in young untreated animals (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). This PPAR&#x003b2;-promoted increment of oxidative capabilities of TLA from aged animals was then confirmed by the determination of citrate synthase (CS) activity as a marker of the oxidative metabolism and lactate dehydrogenase (LDH) activity as a marker of glycolytic metabolism. These experiments showed that, after 4&#x000a0;days of PPAR&#x003b2; agonist treatment, the CS specific activity was increased by 16.7% (<italic>p</italic>&#x02009;=&#x02009;0.002, <italic>n</italic>&#x02009;=&#x02009;4), while the LDH-specific activity remained unchanged (<italic>p</italic>&#x02009;&#x0003e;&#x02009;0.5, <italic>n</italic>&#x02009;=&#x02009;4). Comparable effects were previously reported in PPAR&#x003b2; transgenic animals [<xref ref-type="bibr" rid="CR18">18</xref>]. <table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Ageing promotes a decrease of TLA oxidative fibre proportion, while PPAR&#x003b2; agonist treatment restores a juvenile phenotype</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Age in month</th><th colspan="3">2.5 months</th><th colspan="3">22 months</th></tr><tr><th>C57Bl6 Mice</th><th>Control</th><th>GW96h</th><th><italic>p</italic> value</th><th>Control</th><th>GW96h</th><th><italic>p</italic> value</th></tr></thead><tbody><tr><td>SDH positive (%)</td><td char="&#x000b1;" align="char">46.4&#x02009;&#x000b1;&#x02009;1.3</td><td char="&#x000b1;" align="char">54.6&#x02009;&#x000b1;&#x02009;1.9</td><td char="&#x02212;" align="char">1.5E&#x02212;05</td><td char="&#x000b1;" align="char">39.3&#x02009;&#x000b1;&#x02009;1.4</td><td char="&#x000b1;" align="char">47.6&#x02009;&#x000b1;&#x02009;2.4</td><td char="." align="char">0.0067</td></tr><tr><td>SDH negative (%)</td><td char="&#x000b1;" align="char">53.6&#x02009;&#x000b1;&#x02009;1.3</td><td char="&#x000b1;" align="char">45.4&#x02009;&#x000b1;&#x02009;1.9</td><td char="&#x02212;" align="char">1.5E&#x02212;05</td><td char="&#x000b1;" align="char">60.7&#x02009;&#x000b1;&#x02009;1.4</td><td char="&#x000b1;" align="char">52.4&#x02009;&#x000b1;&#x02009;2.4</td><td char="." align="char">0.0067</td></tr></tbody></table><table-wrap-foot><p>In situ staining of succinate dehydrogenase activity using cross-sections around mid-portion of the TLA muscles from 10-week-old and 22-month-old animals treated or not for 4&#x000a0;days with GW0742</p></table-wrap-foot></table-wrap></p></sec></sec><sec id="Sec8" sec-type="discussion"><title>Discussion</title><p>We previously reported that PPAR&#x003b2; activation or over-expression in mice induces striking skeletal muscle oxidative and angiogenic remodelling [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR18">18</xref>]. We report here a new phenotype in both PPAR&#x003b2; transgenic mice and PPAR&#x003b2; agonist-treated mice, consisting in massive activation, recruitment and fusion of MPCs to both pre-existing and newly formed myofibres. Fusion of such a large number of myonuclei may represent a key event in the PPAR&#x003b2;-promoted oxidative muscle remodelling.</p><p>This newly described PPAR&#x003b2;-promoted phenotype is remarkable in magnitude and quickness. First, in B6D2F1 mice, muscle-specific PPAR&#x003b2; over-expression or pharmacological activation induced a 14% increase in myonuclear density when compared to control animals. This myonuclear density increment is even more pronounced in GW0742-treated C57Bl6 mice which display a 20% augmentation. Taking into account that in the TLA of C57Bl6, PPAR&#x003b2; agonist treatment also leads to a muscle hyperplasia corresponding to the generation of 600 new myofibres [<xref ref-type="bibr" rid="CR10">10</xref>], it can be estimated that PPAR&#x003b2; activation resulted in addition of about one million of new myonuclei to each muscle. Furthermore, these events of MPC activation, recruitment and fusion could also happen in other muscles, resulting in addition of several millions of new myonuclei per animal. The quickness of myonuclear accretion after PPAR&#x003b2; administration is also very impressive. In both C57Bl6 and B6D2F1, GW0742 treatment promoted an increase in myonuclear density that was already detectable at day&#x02009;1 and achieved at day 2 (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). This process takes place in the same time frame that we have already determined for the PPAR&#x003b2;-promoted myogenic/angiogenic muscle remodelling [<xref ref-type="bibr" rid="CR10">10</xref>]. Analysis of the fibre distribution depending on their myonuclear content per millimetre of fibre length (<italic>F</italic>&#x02009;&#x0003c;&#x02009;85; 85&#x02009;&#x0003c;&#x02009;<italic>F</italic>&#x02009;&#x0003c;&#x02009;100; <italic>F</italic>&#x02009;&#x0003e;&#x02009;100) allowed a better description of the effects of PPAR&#x003b2; pathway activation. Both PPAR&#x003b2; over-expression and its pharmacological activation highly increased the number of fibres that contain more than 100 nuclei/mm fibre length (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>b and <xref rid="Fig2" ref-type="fig">2</xref>b). Furthermore, in GW0742-treated animals, we observed a time-dependent shift from the two classes of low myonuclear density fibres towards high myonuclear density fibres. Indeed, in C57Bl6, the fibres that contain less than 100 nuclei (<italic>F</italic>&#x02009;&#x0003c;&#x02009;85 and 85&#x02009;&#x0003c;&#x02009;<italic>F</italic>&#x02009;&#x0003c;&#x02009;100) represent 93% of the myofibres before the treatment, 66% after 1&#x000a0;day of treatment, and only 38% after 2&#x000a0;days of treatment (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>b). Since these fibres did not disappear, the most probable scenario is a rapid and progressive recruitment and fusion of MPCs to pre-existing and newly formed fibres.</p><p>Another remarkable feature of the PPAR&#x003b2;-promoted myonuclear accretion is the finding that proliferation of MPCs is not required for such a remodelling (Figs.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref> and <xref rid="Fig4" ref-type="fig">4</xref>). This is in contrast with other pathological or physiological situations leading to muscle remodelling, such as adaptation to exercise, overload or muscle regeneration, in which a critical and obligatory step of MPCs proliferation has been established [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR26">26</xref>]. However, it should be noted that in these situations, muscle remodelling takes place within weeks and often follows muscle damage, whereas PPAR&#x003b2;-promoted muscle remodelling is achieved in 2&#x000a0;days without any histological sign of fibre deterioration. All our observations argue in favour of a model, in which the PPAR&#x003b2; pathway activates a pool of MPCs that are &#x0201c;committed&#x0201d; to differentiate and able to fuse to fibres omitting the obligate step of proliferation. Existence of such cells has already been suggested by others [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR43">43</xref>].</p><p>The central role of the calcineurin/NFAT pathway in the maintenance of fibre type composition and in muscle adaptation to physical exercise has been well documented (for review, see [<xref ref-type="bibr" rid="CR3">3</xref>]). The calcineurin pathway has also been associated with MPC activation [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR34">34</xref>]. As cyclosporine A administration abolished both myogenic and angiogenic responses to PPAR&#x003b2; activation, we previously proposed that active calcineurin pathway is required for PPAR&#x003b2;-promoted muscle remodelling [<xref ref-type="bibr" rid="CR10">10</xref>]. Data presented here reinforce this model as demonstrating that treatment of mice with GW0742 did not affect calcineurin A expression but induced calcineurin A activation as shown by the rapid nuclearization of both NFATc1 and NFATc3 in TLA (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>). The finding that CsA administration impaired the PPAR&#x003b2;-dependent increase in global myonuclear density (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>a) as well as the redistribution of myofibres in the three defined fibre groups (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>b) strongly suggests that the calcineurin/NFAT pathway is involved directly in the PPAR&#x003b2;-promoted myonuclear accretion. Further work is required to fully characterise the signalling cascade that follows PPAR&#x003b2;-promoted NFAT activation.</p><p>A characteristic of ageing muscle is fibre atrophy and loss of myonuclei [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>]. In particular, the regression in myonuclear content seems to be a key event in the process of age-related muscle atrophy. Our data confirmed that ageing leads to a reduction in global myonuclear density and to a poor fibre distribution profile (Fig.&#x000a0;<xref rid="Fig8" ref-type="fig">8</xref>a, b). Furthermore, ageing results in a reduction of TLA muscle oxidative capabilities (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>), down-regulation of PPAR&#x003b2; expression and transcriptional activity (Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7</xref>). As we have demonstrated that PPAR&#x003b2; pathway activation promotes both oxidative phenotype [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR18">18</xref>] and myonuclear accretion (Figs.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref> and <xref rid="Fig2" ref-type="fig">2</xref>), it is tempting to speculate that PPAR&#x003b2; down-regulation observed in muscle from aged animals is directly involved in the age-related reduction of both myonuclear density and oxidative phenotype in TLA. The findings showing that PPAR&#x003b2; over-expression or pharmacological activation (Fig.&#x000a0;<xref rid="Fig8" ref-type="fig">8</xref>a, b and Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>) counteract, at least in part, the effects of ageing on these parameters suggest that PPAR&#x003b2; activation could exert preventive or curative effects on both age-related muscle atrophy and reduction of oxidative phenotype.</p><p>The effect of such import of new genetic material on the functional and metabolic abilities of muscle cells of treated animals remains to be determined. However, it may represent the basis for the rapid muscle plasticity and adaptation to aerobic exercise, possibly allowing a reprogramming of muscle cells toward a more oxidative phenotype, through an increased coding efficiency for contractile proteins and genes involved in fatty acid oxidation and mitochondrial biogenesis [<xref ref-type="bibr" rid="CR39">39</xref>]. This hypothesis could explain the role of PPAR&#x003b2; induction after various types of physical training [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR42">42</xref>]. Finally, our data indicate that, in addition to its beneficial effects on metabolism, PPAR&#x003b2; agonists may represent a therapeutic approach for the treatment of age-related muscle atrophy.</p></sec></body><back><ack><p>GW0742 was a generous gift from T.M. Willson (GlaxoSmithKline). The CREB antibody was a gift of M. Montminy. We thank E. Lendoye, M. Aupetit, M. Radjkhumar, F. Millot, J. Paput, G. Manfroni and G. Visciano for technical assistance. We thank Dr. Kay-Dietrich Wagner for critical reading of the manuscript. This work was supported by a grant to PG from the Agence Nationale de la Recherche (ANR-05-PCOD-012). NW has a fellowship from the Fondation de France. The authors have no conflicting financial interest.</p><p><bold>Open Access</bold> This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Adams</surname><given-names>GR</given-names></name><name><surname>Haddad</surname><given-names>F</given-names></name><name><surname>Baldwin</surname><given-names>KM</given-names></name></person-group><article-title>Time course of changes in markers of myogenesis in overloaded rat skeletal muscles</article-title><source>J Appl Physiol</source><year>1999</year><volume>87</volume><fpage>1705</fpage><lpage>1712</lpage></citation><citation citation-type="display-unstructured">Adams GR, Haddad F, Baldwin KM (1999) Time course of changes in markers of myogenesis in overloaded rat skeletal muscles. J Appl Physiol 87:1705&#x02013;1712 <pub-id pub-id-type="pmid">10562612</pub-id></citation></ref><ref id="CR2"><label>2.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Allen</surname><given-names>DL</given-names></name><name><surname>Monke</surname><given-names>SR</given-names></name><name><surname>Talmadge</surname><given-names>RJ</given-names></name><name><surname>Roy</surname><given-names>RR</given-names></name><name><surname>Edgerton</surname><given-names>VR</given-names></name></person-group><article-title>Plasticity of myonuclear number in hypertrophied and atrophied mammalian skeletal muscle fibers</article-title><source>J Appl Physiol</source><year>1995</year><volume>78</volume><fpage>1969</fpage><lpage>1976</lpage></citation><citation citation-type="display-unstructured">Allen DL, Monke SR, Talmadge RJ, Roy RR, Edgerton VR (1995) Plasticity of myonuclear number in hypertrophied and atrophied mammalian skeletal muscle fibers. J Appl Physiol 78:1969&#x02013;1976 <pub-id pub-id-type="pmid">7649936</pub-id></citation></ref><ref id="CR3"><label>3.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bassel-Duby</surname><given-names>R</given-names></name><name><surname>Olson</surname><given-names>EN</given-names></name></person-group><article-title>Signaling pathways in skeletal muscle remodeling</article-title><source>Annu Rev Biochem</source><year>2006</year><volume>75</volume><fpage>19</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1146/annurev.biochem.75.103004.142622</pub-id></citation><citation citation-type="display-unstructured">Bassel-Duby R, Olson EN (2006) Signaling pathways in skeletal muscle remodeling. Annu Rev Biochem 75:19&#x02013;37 <pub-id pub-id-type="pmid">16756483</pub-id></citation></ref><ref id="CR4"><label>4.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brack</surname><given-names>AS</given-names></name><name><surname>Bildsoe</surname><given-names>H</given-names></name><name><surname>Hughes</surname><given-names>SM</given-names></name></person-group><article-title>Evidence that satellite cell decrement contributes to preferential decline in nuclear number from large fibres during murine age-related muscle atrophy</article-title><source>J Cell Sci</source><year>2005</year><volume>118</volume><fpage>4813</fpage><lpage>4821</lpage><pub-id pub-id-type="doi">10.1242/jcs.02602</pub-id></citation><citation citation-type="display-unstructured">Brack AS, Bildsoe H, Hughes SM (2005) Evidence that satellite cell decrement contributes to preferential decline in nuclear number from large fibres during murine age-related muscle atrophy. J Cell Sci 118:4813&#x02013;4821 <pub-id pub-id-type="pmid">16219688</pub-id></citation></ref><ref id="CR5"><label>5.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bruusgaard</surname><given-names>JC</given-names></name><name><surname>Liestol</surname><given-names>K</given-names></name><name><surname>Gundersen</surname><given-names>K</given-names></name></person-group><article-title>Distribution of myonuclei and microtubules in live muscle fibers of young, middle-aged, and old mice</article-title><source>J Appl Physiol</source><year>2006</year><volume>100</volume><fpage>2024</fpage><lpage>2030</lpage><pub-id pub-id-type="doi">10.1152/japplphysiol.00913.2005</pub-id></citation><citation citation-type="display-unstructured">Bruusgaard JC, Liestol K, Gundersen K (2006) Distribution of myonuclei and microtubules in live muscle fibers of young, middle-aged, and old mice. J Appl Physiol 100:2024&#x02013;2030 <pub-id pub-id-type="pmid">16497845</pub-id></citation></ref><ref id="CR6"><label>6.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chambers</surname><given-names>RL</given-names></name><name><surname>McDermott</surname><given-names>JC</given-names></name></person-group><article-title>Molecular basis of skeletal muscle regeneration</article-title><source>Can J Appl Physiol</source><year>1996</year><volume>21</volume><fpage>155</fpage><lpage>184</lpage></citation><citation citation-type="display-unstructured">Chambers RL, McDermott JC (1996) Molecular basis of skeletal muscle regeneration. Can J Appl Physiol 21:155&#x02013;184 <pub-id pub-id-type="pmid">8792022</pub-id></citation></ref><ref id="CR7"><label>7.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Degenhardt</surname><given-names>T</given-names></name><name><surname>Saramaki</surname><given-names>A</given-names></name><name><surname>Malinen</surname><given-names>M</given-names></name><name><surname>Rieck</surname><given-names>M</given-names></name><name><surname>Vaisanen</surname><given-names>S</given-names></name><name><surname>Huotari</surname><given-names>A</given-names></name><name><surname>Herzig</surname><given-names>KH</given-names></name><name><surname>Muller</surname><given-names>R</given-names></name><name><surname>Carlberg</surname><given-names>C</given-names></name></person-group><article-title>Three members of the human pyruvate dehydrogenase kinase gene family are direct targets of the peroxisome proliferator-activated receptor beta/delta</article-title><source>J Mol Biol</source><year>2007</year><volume>372</volume><fpage>341</fpage><lpage>355</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2007.06.091</pub-id></citation><citation citation-type="display-unstructured">Degenhardt T, Saramaki A, Malinen M, Rieck M, Vaisanen S, Huotari A, Herzig KH, Muller R, Carlberg C (2007) Three members of the human pyruvate dehydrogenase kinase gene family are direct targets of the peroxisome proliferator-activated receptor beta/delta. J Mol Biol 372:341&#x02013;355 <pub-id pub-id-type="pmid">17669420</pub-id></citation></ref><ref id="CR8"><label>8.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Friday</surname><given-names>BB</given-names></name><name><surname>Pavlath</surname><given-names>GK</given-names></name></person-group><article-title>A calcineurin- and NFAT-dependent pathway regulates Myf5 gene expression in skeletal muscle reserve cells</article-title><source>J Cell Sci</source><year>2001</year><volume>114</volume><fpage>303</fpage><lpage>310</lpage></citation><citation citation-type="display-unstructured">Friday BB, Pavlath GK (2001) A calcineurin- and NFAT-dependent pathway regulates Myf5 gene expression in skeletal muscle reserve cells. J Cell Sci 114:303&#x02013;310 <pub-id pub-id-type="pmid">11148132</pub-id></citation></ref><ref id="CR9"><label>9.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fritz</surname><given-names>T</given-names></name><name><surname>Kramer</surname><given-names>DK</given-names></name><name><surname>Karlsson</surname><given-names>HK</given-names></name><name><surname>Galuska</surname><given-names>D</given-names></name><name><surname>Engfeldt</surname><given-names>P</given-names></name><name><surname>Zierath</surname><given-names>JR</given-names></name><name><surname>Krook</surname><given-names>A</given-names></name></person-group><article-title>Low-intensity exercise increases skeletal muscle protein expression of PPARdelta and UCP3 in type 2 diabetic patients</article-title><source>Diabetes Metab Res Rev</source><year>2006</year><volume>22</volume><fpage>492</fpage><lpage>498</lpage><pub-id pub-id-type="doi">10.1002/dmrr.656</pub-id></citation><citation citation-type="display-unstructured">Fritz T, Kramer DK, Karlsson HK, Galuska D, Engfeldt P, Zierath JR, Krook A (2006) Low-intensity exercise increases skeletal muscle protein expression of PPARdelta and UCP3 in type 2 diabetic patients. Diabetes Metab Res Rev 22:492&#x02013;498 <pub-id pub-id-type="pmid">16752430</pub-id></citation></ref><ref id="CR10"><label>10.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gaudel</surname><given-names>C</given-names></name><name><surname>Schwartz</surname><given-names>C</given-names></name><name><surname>Giordano</surname><given-names>C</given-names></name><name><surname>Abumrad</surname><given-names>NA</given-names></name><name><surname>Grimaldi</surname><given-names>P</given-names></name></person-group><article-title>Pharmacological activation of PPAR{beta} promotes rapid and calcineurin-dependent fiber remodeling and angiogenesis in mouse skeletal muscle</article-title><source>Am J Physiol Endocrinol Metab</source><year>2008</year><volume>295</volume><fpage>E297</fpage><lpage>E304</lpage><pub-id pub-id-type="doi">10.1152/ajpendo.00581.2007</pub-id></citation><citation citation-type="display-unstructured">Gaudel C, Schwartz C, Giordano C, Abumrad NA, Grimaldi P (2008) Pharmacological activation of PPAR{beta} promotes rapid and calcineurin-dependent fiber remodeling and angiogenesis in mouse skeletal muscle. Am J Physiol Endocrinol Metab 295:E297&#x02013;E304 <pub-id pub-id-type="pmid">18492772</pub-id></citation></ref><ref id="CR11"><label>11.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Grounds</surname><given-names>MD</given-names></name><name><surname>Garrett</surname><given-names>KL</given-names></name><name><surname>Lai</surname><given-names>MC</given-names></name><name><surname>Wright</surname><given-names>WE</given-names></name><name><surname>Beilharz</surname><given-names>MW</given-names></name></person-group><article-title>Identification of skeletal muscle precursor cells in vivo by use of MyoD1 and myogenin probes</article-title><source>Cell Tissue Res</source><year>1992</year><volume>267</volume><fpage>99</fpage><lpage>104</lpage><pub-id pub-id-type="doi">10.1007/BF00318695</pub-id></citation><citation citation-type="display-unstructured">Grounds MD, Garrett KL, Lai MC, Wright WE, Beilharz MW (1992) Identification of skeletal muscle precursor cells in vivo by use of MyoD1 and myogenin probes. Cell Tissue Res 267:99&#x02013;104 <pub-id pub-id-type="pmid">1310442</pub-id></citation></ref><ref id="CR12"><label>12.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Haddad</surname><given-names>F</given-names></name><name><surname>Adams</surname><given-names>GR</given-names></name></person-group><article-title>Aging-sensitive cellular and molecular mechanisms associated with skeletal muscle hypertrophy</article-title><source>J Appl Physiol</source><year>2006</year><volume>100</volume><fpage>1188</fpage><lpage>1203</lpage><pub-id pub-id-type="doi">10.1152/japplphysiol.01227.2005</pub-id></citation><citation citation-type="display-unstructured">Haddad F, Adams GR (2006) Aging-sensitive cellular and molecular mechanisms associated with skeletal muscle hypertrophy. J Appl Physiol 100:1188&#x02013;1203 <pub-id pub-id-type="pmid">16373446</pub-id></citation></ref><ref id="CR13"><label>13.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hughes</surname><given-names>SM</given-names></name><name><surname>Schiaffino</surname><given-names>S</given-names></name></person-group><article-title>Control of muscle fibre size: a crucial factor in ageing</article-title><source>Acta Physiol Scand</source><year>1999</year><volume>167</volume><fpage>307</fpage><lpage>312</lpage><pub-id pub-id-type="doi">10.1046/j.1365-201x.1999.00619.x</pub-id></citation><citation citation-type="display-unstructured">Hughes SM, Schiaffino S (1999) Control of muscle fibre size: a crucial factor in ageing. Acta Physiol Scand 167:307&#x02013;312 <pub-id pub-id-type="pmid">10632631</pub-id></citation></ref><ref id="CR14"><label>14.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ishido</surname><given-names>M</given-names></name><name><surname>Kami</surname><given-names>K</given-names></name><name><surname>Masuhara</surname><given-names>M</given-names></name></person-group><article-title>Localization of MyoD, myogenin and cell cycle regulatory factors in hypertrophying rat skeletal muscles</article-title><source>Acta Physiol Scand</source><year>2004</year><volume>180</volume><fpage>281</fpage><lpage>289</lpage><pub-id pub-id-type="doi">10.1046/j.0001-6772.2003.01238.x</pub-id></citation><citation citation-type="display-unstructured">Ishido M, Kami K, Masuhara M (2004) Localization of MyoD, myogenin and cell cycle regulatory factors in hypertrophying rat skeletal muscles. Acta Physiol Scand 180:281&#x02013;289 <pub-id pub-id-type="pmid">14962010</pub-id></citation></ref><ref id="CR15"><label>15.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Leibowitz</surname><given-names>MD</given-names></name><name><surname>Fievet</surname><given-names>C</given-names></name><name><surname>Hennuyer</surname><given-names>N</given-names></name><name><surname>Peinado-Onsurbe</surname><given-names>J</given-names></name><name><surname>Duez</surname><given-names>H</given-names></name><name><surname>Bergera</surname><given-names>J</given-names></name><name><surname>Cullinan</surname><given-names>CA</given-names></name><name><surname>Sparrow</surname><given-names>CP</given-names></name><name><surname>Baffic</surname><given-names>J</given-names></name><name><surname>Berger</surname><given-names>GD</given-names></name><name><surname>Santini</surname><given-names>C</given-names></name><name><surname>Marquis</surname><given-names>RW</given-names></name><name><surname>Tolman</surname><given-names>RL</given-names></name><name><surname>Smith</surname><given-names>RG</given-names></name><name><surname>Moller</surname><given-names>DE</given-names></name><name><surname>Auwerx</surname><given-names>J</given-names></name></person-group><article-title>Activation of PPARdelta alters lipid metabolism in db/db mice</article-title><source>FEBS Lett</source><year>2000</year><volume>473</volume><fpage>333</fpage><lpage>336</lpage><pub-id pub-id-type="doi">10.1016/S0014-5793(00)01554-4</pub-id></citation><citation citation-type="display-unstructured">Leibowitz MD, Fievet C, Hennuyer N, Peinado-Onsurbe J, Duez H, Bergera J, Cullinan CA, Sparrow CP, Baffic J, Berger GD, Santini C, Marquis RW, Tolman RL, Smith RG, Moller DE, Auwerx J (2000) Activation of PPARdelta alters lipid metabolism in db/db mice. FEBS Lett 473:333&#x02013;336 <pub-id pub-id-type="pmid">10818235</pub-id></citation></ref><ref id="CR16"><label>16.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>P</given-names></name><name><surname>Akimoto</surname><given-names>T</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Williams</surname><given-names>RS</given-names></name><name><surname>Yan</surname><given-names>Z</given-names></name></person-group><article-title>Resident stem cells are not required for exercise-induced fiber-type switching and angiogenesis but are necessary for activity-dependent muscle growth</article-title><source>Am J Physiol Cell Physiol</source><year>2006</year><volume>290</volume><fpage>C1461</fpage><lpage>1468</lpage><pub-id pub-id-type="doi">10.1152/ajpcell.00532.2005</pub-id></citation><citation citation-type="display-unstructured">Li P, Akimoto T, Zhang M, Williams RS, Yan Z (2006) Resident stem cells are not required for exercise-induced fiber-type switching and angiogenesis but are necessary for activity-dependent muscle growth. Am J Physiol Cell Physiol 290:C1461&#x02013;1468 <pub-id pub-id-type="pmid">16407413</pub-id></citation></ref><ref id="CR17"><label>17.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Luquet</surname><given-names>S</given-names></name><name><surname>Gaudel</surname><given-names>C</given-names></name><name><surname>Holst</surname><given-names>D</given-names></name><name><surname>Lopez-Soriano</surname><given-names>J</given-names></name><name><surname>Jehl-Pietri</surname><given-names>C</given-names></name><name><surname>Fredenrich</surname><given-names>A</given-names></name><name><surname>Grimaldi</surname><given-names>PA</given-names></name></person-group><article-title>Roles of PPAR delta in lipid absorption and metabolism: a new target for the treatment of type 2 diabetes</article-title><source>Biochim Biophys Acta</source><year>2005</year><volume>1740</volume><fpage>313</fpage><lpage>317</lpage></citation><citation citation-type="display-unstructured">Luquet S, Gaudel C, Holst D, Lopez-Soriano J, Jehl-Pietri C, Fredenrich A, Grimaldi PA (2005) Roles of PPAR delta in lipid absorption and metabolism: a new target for the treatment of type 2 diabetes. Biochim Biophys Acta 1740:313&#x02013;317 <pub-id pub-id-type="pmid">15949697</pub-id></citation></ref><ref id="CR18"><label>18.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Luquet</surname><given-names>S</given-names></name><name><surname>Lopez-Soriano</surname><given-names>J</given-names></name><name><surname>Holst</surname><given-names>D</given-names></name><name><surname>Fredenrich</surname><given-names>A</given-names></name><name><surname>Melki</surname><given-names>J</given-names></name><name><surname>Rassoulzadegan</surname><given-names>M</given-names></name><name><surname>Grimaldi</surname><given-names>PA</given-names></name></person-group><article-title>Peroxisome proliferator-activated receptor delta controls muscle development and oxidative capability</article-title><source>Faseb J</source><year>2003</year><volume>17</volume><fpage>2299</fpage><lpage>2301</lpage></citation><citation citation-type="display-unstructured">Luquet S, Lopez-Soriano J, Holst D, Fredenrich A, Melki J, Rassoulzadegan M, Grimaldi PA (2003) Peroxisome proliferator-activated receptor delta controls muscle development and oxidative capability. Faseb J 17:2299&#x02013;2301 <pub-id pub-id-type="pmid">14525942</pub-id></citation></ref><ref id="CR19"><label>19.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mauro</surname><given-names>A</given-names></name></person-group><article-title>Satellite cell of skeletal muscle fibers</article-title><source>J Biophys Biochem Cytol</source><year>1961</year><volume>9</volume><fpage>493</fpage><lpage>495</lpage></citation><citation citation-type="display-unstructured">Mauro A (1961) Satellite cell of skeletal muscle fibers. J Biophys Biochem Cytol 9:493&#x02013;495 <pub-id pub-id-type="pmid">13768451</pub-id></citation></ref><ref id="CR20"><label>20.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Miniou</surname><given-names>P</given-names></name><name><surname>Tiziano</surname><given-names>D</given-names></name><name><surname>Frugier</surname><given-names>T</given-names></name><name><surname>Roblot</surname><given-names>N</given-names></name><name><surname>Meur</surname><given-names>M</given-names></name><name><surname>Melki</surname><given-names>J</given-names></name></person-group><article-title>Gene targeting restricted to mouse striated muscle lineage</article-title><source>Nucleic Acids Res</source><year>1999</year><volume>27</volume><fpage>e27</fpage><pub-id pub-id-type="doi">10.1093/nar/27.19.e27</pub-id></citation><citation citation-type="display-unstructured">Miniou P, Tiziano D, Frugier T, Roblot N, Le Meur M, Melki J (1999) Gene targeting restricted to mouse striated muscle lineage. Nucleic Acids Res 27:e27 <pub-id pub-id-type="pmid">10481039</pub-id></citation></ref><ref id="CR21"><label>21.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Oliver</surname><given-names>WR</given-names><suffix>Jr</suffix></name><name><surname>Shenk</surname><given-names>JL</given-names></name><name><surname>Snaith</surname><given-names>MR</given-names></name><name><surname>Russell</surname><given-names>CS</given-names></name><name><surname>Plunket</surname><given-names>KD</given-names></name><name><surname>Bodkin</surname><given-names>NL</given-names></name><name><surname>Lewis</surname><given-names>MC</given-names></name><name><surname>Winegar</surname><given-names>DA</given-names></name><name><surname>Sznaidman</surname><given-names>ML</given-names></name><name><surname>Lambert</surname><given-names>MH</given-names></name><name><surname>Xu</surname><given-names>HE</given-names></name><name><surname>Sternbach</surname><given-names>DD</given-names></name><name><surname>Kliewer</surname><given-names>SA</given-names></name><name><surname>Hansen</surname><given-names>BC</given-names></name><name><surname>Willson</surname><given-names>TM</given-names></name></person-group><article-title>A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport</article-title><source>Proc Natl Acad Sci U S A</source><year>2001</year><volume>98</volume><fpage>5306</fpage><lpage>5311</lpage><pub-id pub-id-type="doi">10.1073/pnas.091021198</pub-id></citation><citation citation-type="display-unstructured">Oliver WR Jr, Shenk JL, Snaith MR, Russell CS, Plunket KD, Bodkin NL, Lewis MC, Winegar DA, Sznaidman ML, Lambert MH, Xu HE, Sternbach DD, Kliewer SA, Hansen BC, Willson TM (2001) A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. Proc Natl Acad Sci U S A 98:5306&#x02013;5311 <pub-id pub-id-type="pmid">11309497</pub-id></citation></ref><ref id="CR22"><label>22.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Perez-Ruiz</surname><given-names>A</given-names></name><name><surname>Gnocchi</surname><given-names>VF</given-names></name><name><surname>Zammit</surname><given-names>PS</given-names></name></person-group><article-title>Control of Myf5 activation in adult skeletal myonuclei requires ERK signalling</article-title><source>Cell Signal</source><year>2007</year><volume>19</volume><fpage>1671</fpage><lpage>1680</lpage><pub-id pub-id-type="doi">10.1016/j.cellsig.2007.03.003</pub-id></citation><citation citation-type="display-unstructured">Perez-Ruiz A, Gnocchi VF, Zammit PS (2007) Control of Myf5 activation in adult skeletal myonuclei requires ERK signalling. Cell Signal 19:1671&#x02013;1680 <pub-id pub-id-type="pmid">17481856</pub-id></citation></ref><ref id="CR23"><label>23.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pesant</surname><given-names>M</given-names></name><name><surname>Sueur</surname><given-names>S</given-names></name><name><surname>Dutartre</surname><given-names>P</given-names></name><name><surname>Tallandier</surname><given-names>M</given-names></name><name><surname>Grimaldi</surname><given-names>PA</given-names></name><name><surname>Rochette</surname><given-names>L</given-names></name><name><surname>Connat</surname><given-names>JL</given-names></name></person-group><article-title>Peroxisome proliferator-activated receptor delta (PPARdelta) activation protects H9c2 cardiomyoblasts from oxidative stress-induced apoptosis</article-title><source>Cardiovasc Res</source><year>2006</year><volume>69</volume><fpage>440</fpage><lpage>449</lpage><pub-id pub-id-type="doi">10.1016/j.cardiores.2005.10.019</pub-id></citation><citation citation-type="display-unstructured">Pesant M, Sueur S, Dutartre P, Tallandier M, Grimaldi PA, Rochette L, Connat JL (2006) Peroxisome proliferator-activated receptor delta (PPARdelta) activation protects H9c2 cardiomyoblasts from oxidative stress-induced apoptosis. Cardiovasc Res 69:440&#x02013;449 <pub-id pub-id-type="pmid">16337160</pub-id></citation></ref><ref id="CR24"><label>24.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rantanen</surname><given-names>J</given-names></name><name><surname>Hurme</surname><given-names>T</given-names></name><name><surname>Lukka</surname><given-names>R</given-names></name><name><surname>Heino</surname><given-names>J</given-names></name><name><surname>Kalimo</surname><given-names>H</given-names></name></person-group><article-title>Satellite cell proliferation and the expression of myogenin and desmin in regenerating skeletal muscle: evidence for two different populations of satellite cells</article-title><source>Lab Invest</source><year>1995</year><volume>72</volume><fpage>341</fpage><lpage>347</lpage></citation><citation citation-type="display-unstructured">Rantanen J, Hurme T, Lukka R, Heino J, Kalimo H (1995) Satellite cell proliferation and the expression of myogenin and desmin in regenerating skeletal muscle: evidence for two different populations of satellite cells. Lab Invest 72:341&#x02013;347 <pub-id pub-id-type="pmid">7898053</pub-id></citation></ref><ref id="CR25"><label>25.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Robertson</surname><given-names>TA</given-names></name><name><surname>Grounds</surname><given-names>MD</given-names></name><name><surname>Mitchell</surname><given-names>CA</given-names></name><name><surname>Papadimitriou</surname><given-names>JM</given-names></name></person-group><article-title>Fusion between myogenic cells in vivo: an ultrastructural study in regenerating murine skeletal muscle</article-title><source>J Struct Biol</source><year>1990</year><volume>105</volume><fpage>170</fpage><lpage>182</lpage><pub-id pub-id-type="doi">10.1016/1047-8477(90)90111-O</pub-id></citation><citation citation-type="display-unstructured">Robertson TA, Grounds MD, Mitchell CA, Papadimitriou JM (1990) Fusion between myogenic cells in vivo: an ultrastructural study in regenerating murine skeletal muscle. J Struct Biol 105:170&#x02013;182 <pub-id pub-id-type="pmid">2100148</pub-id></citation></ref><ref id="CR26"><label>26.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Robertson</surname><given-names>TA</given-names></name><name><surname>Grounds</surname><given-names>MD</given-names></name><name><surname>Papadimitriou</surname><given-names>JM</given-names></name></person-group><article-title>Elucidation of aspects of murine skeletal muscle regeneration using local and whole body irradiation</article-title><source>J Anat</source><year>1992</year><volume>181</volume><issue>Pt 2</issue><fpage>265</fpage><lpage>276</lpage></citation><citation citation-type="display-unstructured">Robertson TA, Grounds MD, Papadimitriou JM (1992) Elucidation of aspects of murine skeletal muscle regeneration using local and whole body irradiation. J Anat 181(Pt 2):265&#x02013;276 <pub-id pub-id-type="pmid">1295865</pub-id></citation></ref><ref id="CR27"><label>27.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Robertson</surname><given-names>TA</given-names></name><name><surname>Papadimitriou</surname><given-names>JM</given-names></name><name><surname>Grounds</surname><given-names>MD</given-names></name></person-group><article-title>Fusion between a myogenic cell in the satellite cell position and undamaged adult myofibre segments</article-title><source>Experientia</source><year>1992</year><volume>48</volume><fpage>394</fpage><lpage>395</lpage><pub-id pub-id-type="doi">10.1007/BF01923439</pub-id></citation><citation citation-type="display-unstructured">Robertson TA, Papadimitriou JM, Grounds MD (1992) Fusion between a myogenic cell in the satellite cell position and undamaged adult myofibre segments. Experientia 48:394&#x02013;395 <pub-id pub-id-type="pmid">1582497</pub-id></citation></ref><ref id="CR28"><label>28.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Robertson</surname><given-names>TA</given-names></name><name><surname>Papadimitriou</surname><given-names>JM</given-names></name><name><surname>Grounds</surname><given-names>MD</given-names></name></person-group><article-title>Fusion of myogenic cells to the newly sealed region of damaged myofibres in skeletal muscle regeneration</article-title><source>Neuropathol Appl Neurobiol</source><year>1993</year><volume>19</volume><fpage>350</fpage><lpage>358</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2990.1993.tb00451.x</pub-id></citation><citation citation-type="display-unstructured">Robertson TA, Papadimitriou JM, Grounds MD (1993) Fusion of myogenic cells to the newly sealed region of damaged myofibres in skeletal muscle regeneration. Neuropathol Appl Neurobiol 19:350&#x02013;358 <pub-id pub-id-type="pmid">8232756</pub-id></citation></ref><ref id="CR29"><label>29.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rosenblatt</surname><given-names>JD</given-names></name><name><surname>Yong</surname><given-names>D</given-names></name><name><surname>Parry</surname><given-names>DJ</given-names></name></person-group><article-title>Satellite cell activity is required for hypertrophy of overloaded adult rat muscle</article-title><source>Muscle Nerve</source><year>1994</year><volume>17</volume><fpage>608</fpage><lpage>613</lpage><pub-id pub-id-type="doi">10.1002/mus.880170607</pub-id></citation><citation citation-type="display-unstructured">Rosenblatt JD, Yong D, Parry DJ (1994) Satellite cell activity is required for hypertrophy of overloaded adult rat muscle. Muscle Nerve 17:608&#x02013;613 <pub-id pub-id-type="pmid">8196703</pub-id></citation></ref><ref id="CR30"><label>30.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Roy</surname><given-names>RR</given-names></name><name><surname>Monke</surname><given-names>SR</given-names></name><name><surname>Allen</surname><given-names>DL</given-names></name><name><surname>Edgerton</surname><given-names>VR</given-names></name></person-group><article-title>Modulation of myonuclear number in functionally overloaded and exercised rat plantaris fibers</article-title><source>J Appl Physiol</source><year>1999</year><volume>87</volume><fpage>634</fpage><lpage>642</lpage></citation><citation citation-type="display-unstructured">Roy RR, Monke SR, Allen DL, Edgerton VR (1999) Modulation of myonuclear number in functionally overloaded and exercised rat plantaris fibers. J Appl Physiol 87:634&#x02013;642 <pub-id pub-id-type="pmid">10444623</pub-id></citation></ref><ref id="CR31"><label>31.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sabourin</surname><given-names>LA</given-names></name><name><surname>Rudnicki</surname><given-names>MA</given-names></name></person-group><article-title>The molecular regulation of myogenesis</article-title><source>Clin Genet</source><year>2000</year><volume>57</volume><fpage>16</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1034/j.1399-0004.2000.570103.x</pub-id></citation><citation citation-type="display-unstructured">Sabourin LA, Rudnicki MA (2000) The molecular regulation of myogenesis. Clin Genet 57:16&#x02013;25 <pub-id pub-id-type="pmid">10733231</pub-id></citation></ref><ref id="CR32"><label>32.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Salleo</surname><given-names>A</given-names></name><name><surname>Spada</surname><given-names>G</given-names></name><name><surname>Falzea</surname><given-names>G</given-names></name><name><surname>Denaro</surname><given-names>MG</given-names></name><name><surname>Cicciarello</surname><given-names>R</given-names></name></person-group><article-title>Response of satellite cells and muscle fibers to long-term compensatory hypertrophy</article-title><source>J Submicrosc Cytol</source><year>1983</year><volume>15</volume><fpage>929</fpage><lpage>940</lpage></citation><citation citation-type="display-unstructured">Salleo A, La Spada G, Falzea G, Denaro MG, Cicciarello R (1983) Response of satellite cells and muscle fibers to long-term compensatory hypertrophy. J Submicrosc Cytol 15:929&#x02013;940 <pub-id pub-id-type="pmid">6655769</pub-id></citation></ref><ref id="CR33"><label>33.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schultz</surname><given-names>E</given-names></name></person-group><article-title>Satellite cell behavior during skeletal muscle growth and regeneration</article-title><source>Med Sci Sports Exerc</source><year>1989</year><volume>21</volume><fpage>S181</fpage><lpage>186</lpage></citation><citation citation-type="display-unstructured">Schultz E (1989) Satellite cell behavior during skeletal muscle growth and regeneration. Med Sci Sports Exerc 21:S181&#x02013;186 <pub-id pub-id-type="pmid">2691829</pub-id></citation></ref><ref id="CR34"><label>34.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Scicchitano</surname><given-names>BM</given-names></name><name><surname>Spath</surname><given-names>L</given-names></name><name><surname>Musaro</surname><given-names>A</given-names></name><name><surname>Molinaro</surname><given-names>M</given-names></name><name><surname>Rosenthal</surname><given-names>N</given-names></name><name><surname>Nervi</surname><given-names>C</given-names></name><name><surname>Adamo</surname><given-names>S</given-names></name></person-group><article-title>Vasopressin-dependent myogenic cell differentiation is mediated by both Ca2+/calmodulin-dependent kinase and calcineurin pathways</article-title><source>Mol Biol Cell</source><year>2005</year><volume>16</volume><fpage>3632</fpage><lpage>3641</lpage><pub-id pub-id-type="doi">10.1091/mbc.E05-01-0055</pub-id></citation><citation citation-type="display-unstructured">Scicchitano BM, Spath L, Musaro A, Molinaro M, Rosenthal N, Nervi C, Adamo S (2005) Vasopressin-dependent myogenic cell differentiation is mediated by both Ca2+/calmodulin-dependent kinase and calcineurin pathways. Mol Biol Cell 16:3632&#x02013;3641 <pub-id pub-id-type="pmid">15930130</pub-id></citation></ref><ref id="CR35"><label>35.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>HK</given-names></name><name><surname>Maxwell</surname><given-names>L</given-names></name><name><surname>Rodgers</surname><given-names>CD</given-names></name><name><surname>McKee</surname><given-names>NH</given-names></name><name><surname>Plyley</surname><given-names>MJ</given-names></name></person-group><article-title>Exercise-enhanced satellite cell proliferation and new myonuclear accretion in rat skeletal muscle</article-title><source>J Appl Physiol</source><year>2001</year><volume>90</volume><fpage>1407</fpage><lpage>1414</lpage><pub-id pub-id-type="doi">10.1063/1.1383983</pub-id></citation><citation citation-type="display-unstructured">Smith HK, Maxwell L, Rodgers CD, McKee NH, Plyley MJ (2001) Exercise-enhanced satellite cell proliferation and new myonuclear accretion in rat skeletal muscle. J Appl Physiol 90:1407&#x02013;1414 <pub-id pub-id-type="pmid">11247941</pub-id></citation></ref><ref id="CR36"><label>36.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sprecher</surname><given-names>DL</given-names></name><name><surname>Massien</surname><given-names>C</given-names></name><name><surname>Pearce</surname><given-names>G</given-names></name><name><surname>Billin</surname><given-names>AN</given-names></name><name><surname>Perlstein</surname><given-names>I</given-names></name><name><surname>Willson</surname><given-names>TM</given-names></name><name><surname>Hassall</surname><given-names>DG</given-names></name><name><surname>Ancellin</surname><given-names>N</given-names></name><name><surname>Patterson</surname><given-names>SD</given-names></name><name><surname>Lobe</surname><given-names>DC</given-names></name><name><surname>Johnson</surname><given-names>TG</given-names></name></person-group><article-title>Triglyceride:high-density lipoprotein cholesterol effects in healthy subjects administered a peroxisome proliferator activated receptor delta agonist</article-title><source>Arterioscler Thromb Vasc Biol</source><year>2007</year><volume>27</volume><fpage>359</fpage><lpage>365</lpage><pub-id pub-id-type="doi">10.1161/01.ATV.0000252790.70572.0c</pub-id></citation><citation citation-type="display-unstructured">Sprecher DL, Massien C, Pearce G, Billin AN, Perlstein I, Willson TM, Hassall DG, Ancellin N, Patterson SD, Lobe DC, Johnson TG (2007) Triglyceride:high-density lipoprotein cholesterol effects in healthy subjects administered a peroxisome proliferator activated receptor delta agonist. Arterioscler Thromb Vasc Biol 27:359&#x02013;365 <pub-id pub-id-type="pmid">17110604</pub-id></citation></ref><ref id="CR37"><label>37.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stockdale</surname><given-names>FE</given-names></name><name><surname>Holtzer</surname><given-names>H</given-names></name></person-group><article-title>DNA synthesis and myogenesis</article-title><source>Exp Cell Res</source><year>1961</year><volume>24</volume><fpage>508</fpage><lpage>520</lpage><pub-id pub-id-type="doi">10.1016/0014-4827(61)90450-5</pub-id></citation><citation citation-type="display-unstructured">Stockdale FE, Holtzer H (1961) DNA synthesis and myogenesis. Exp Cell Res 24:508&#x02013;520 <pub-id pub-id-type="pmid">13917284</pub-id></citation></ref><ref id="CR38"><label>38.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sznaidman</surname><given-names>ML</given-names></name><name><surname>Haffner</surname><given-names>CD</given-names></name><name><surname>Maloney</surname><given-names>PR</given-names></name><name><surname>Fivush</surname><given-names>A</given-names></name><name><surname>Chao</surname><given-names>E</given-names></name><name><surname>Goreham</surname><given-names>D</given-names></name><name><surname>Sierra</surname><given-names>ML</given-names></name><name><surname>LeGrumelec</surname><given-names>C</given-names></name><name><surname>Xu</surname><given-names>HE</given-names></name><name><surname>Montana</surname><given-names>VG</given-names></name><name><surname>Lambert</surname><given-names>MH</given-names></name><name><surname>Willson</surname><given-names>TM</given-names></name><name><surname>Oliver</surname><given-names>WR</given-names><suffix>Jr</suffix></name><name><surname>Sternbach</surname><given-names>DD</given-names></name></person-group><article-title>Novel selective small molecule agonists for peroxisome proliferator-activated receptor delta (PPARdelta)&#x02014;synthesis and biological activity</article-title><source>Bioorg Med Chem Lett</source><year>2003</year><volume>13</volume><fpage>1517</fpage><lpage>1521</lpage><pub-id pub-id-type="doi">10.1016/S0960-894X(03)00207-5</pub-id></citation><citation citation-type="display-unstructured">Sznaidman ML, Haffner CD, Maloney PR, Fivush A, Chao E, Goreham D, Sierra ML, LeGrumelec C, Xu HE, Montana VG, Lambert MH, Willson TM, Oliver WR Jr, Sternbach DD (2003) Novel selective small molecule agonists for peroxisome proliferator-activated receptor delta (PPARdelta)&#x02014;synthesis and biological activity. Bioorg Med Chem Lett 13:1517&#x02013;1521 <pub-id pub-id-type="pmid">12699745</pub-id></citation></ref><ref id="CR39"><label>39.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tseng</surname><given-names>BS</given-names></name><name><surname>Kasper</surname><given-names>CE</given-names></name><name><surname>Edgerton</surname><given-names>VR</given-names></name></person-group><article-title>Cytoplasm-to-myonucleus ratios and succinate dehydrogenase activities in adult rat slow and fast muscle fibers</article-title><source>Cell Tissue Res</source><year>1994</year><volume>275</volume><fpage>39</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1007/BF00305374</pub-id></citation><citation citation-type="display-unstructured">Tseng BS, Kasper CE, Edgerton VR (1994) Cytoplasm-to-myonucleus ratios and succinate dehydrogenase activities in adult rat slow and fast muscle fibers. Cell Tissue Res 275:39&#x02013;49 <pub-id pub-id-type="pmid">8118846</pub-id></citation></ref><ref id="CR40"><label>40.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wagers</surname><given-names>AJ</given-names></name><name><surname>Conboy</surname><given-names>IM</given-names></name></person-group><article-title>Cellular and molecular signatures of muscle regeneration: current concepts and controversies in adult myogenesis</article-title><source>Cell</source><year>2005</year><volume>122</volume><fpage>659</fpage><lpage>667</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2005.08.021</pub-id></citation><citation citation-type="display-unstructured">Wagers AJ, Conboy IM (2005) Cellular and molecular signatures of muscle regeneration: current concepts and controversies in adult myogenesis. Cell 122:659&#x02013;667 <pub-id pub-id-type="pmid">16143100</pub-id></citation></ref><ref id="CR41"><label>41.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>YX</given-names></name><name><surname>Lee</surname><given-names>CH</given-names></name><name><surname>Tiep</surname><given-names>S</given-names></name><name><surname>Yu</surname><given-names>RT</given-names></name><name><surname>Ham</surname><given-names>J</given-names></name><name><surname>Kang</surname><given-names>H</given-names></name><name><surname>Evans</surname><given-names>RM</given-names></name></person-group><article-title>Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity</article-title><source>Cell</source><year>2003</year><volume>113</volume><fpage>159</fpage><lpage>170</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(03)00269-1</pub-id></citation><citation citation-type="display-unstructured">Wang YX, Lee CH, Tiep S, Yu RT, Ham J, Kang H, Evans RM (2003) Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity. Cell 113:159&#x02013;170 <pub-id pub-id-type="pmid">12705865</pub-id></citation></ref><ref id="CR42"><label>42.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Watt</surname><given-names>MJ</given-names></name><name><surname>Southgate</surname><given-names>RJ</given-names></name><name><surname>Holmes</surname><given-names>AG</given-names></name><name><surname>Febbraio</surname><given-names>MA</given-names></name></person-group><article-title>Suppression of plasma free fatty acids upregulates peroxisome proliferator-activated receptor (PPAR) alpha and delta and PPAR coactivator 1alpha in human skeletal muscle, but not lipid regulatory genes</article-title><source>J Mol Endocrinol</source><year>2004</year><volume>33</volume><fpage>533</fpage><lpage>544</lpage><pub-id pub-id-type="doi">10.1677/jme.1.01499</pub-id></citation><citation citation-type="display-unstructured">Watt MJ, Southgate RJ, Holmes AG, Febbraio MA (2004) Suppression of plasma free fatty acids upregulates peroxisome proliferator-activated receptor (PPAR) alpha and delta and PPAR coactivator 1alpha in human skeletal muscle, but not lipid regulatory genes. J Mol Endocrinol 33:533&#x02013;544 <pub-id pub-id-type="pmid">15525607</pub-id></citation></ref><ref id="CR43"><label>43.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yablonka-Reuveni</surname><given-names>Z</given-names></name></person-group><article-title>Development and postnatal regulation of adult myoblasts</article-title><source>Microsc Res Tech</source><year>1995</year><volume>30</volume><fpage>366</fpage><lpage>380</lpage><pub-id pub-id-type="doi">10.1002/jemt.1070300504</pub-id></citation><citation citation-type="display-unstructured">Yablonka-Reuveni Z (1995) Development and postnatal regulation of adult myoblasts. Microsc Res Tech 30:366&#x02013;380 <pub-id pub-id-type="pmid">7787236</pub-id></citation></ref><ref id="CR44"><label>44.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zammit</surname><given-names>PS</given-names></name><name><surname>Heslop</surname><given-names>L</given-names></name><name><surname>Hudon</surname><given-names>V</given-names></name><name><surname>Rosenblatt</surname><given-names>JD</given-names></name><name><surname>Tajbakhsh</surname><given-names>S</given-names></name><name><surname>Buckingham</surname><given-names>ME</given-names></name><name><surname>Beauchamp</surname><given-names>JR</given-names></name><name><surname>Partridge</surname><given-names>TA</given-names></name></person-group><article-title>Kinetics of myoblast proliferation show that resident satellite cells are competent to fully regenerate skeletal muscle fibers</article-title><source>Exp Cell Res</source><year>2002</year><volume>281</volume><fpage>39</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1006/excr.2002.5653</pub-id></citation><citation citation-type="display-unstructured">Zammit PS, Heslop L, Hudon V, Rosenblatt JD, Tajbakhsh S, Buckingham ME, Beauchamp JR, Partridge TA (2002) Kinetics of myoblast proliferation show that resident satellite cells are competent to fully regenerate skeletal muscle fibers. Exp Cell Res 281:39&#x02013;49 <pub-id pub-id-type="pmid">12441128</pub-id></citation></ref><ref id="CR45"><label>45.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhong</surname><given-names>H</given-names></name><name><surname>Roy</surname><given-names>RR</given-names></name><name><surname>Siengthai</surname><given-names>B</given-names></name><name><surname>Edgerton</surname><given-names>VR</given-names></name></person-group><article-title>Effects of inactivity on fiber size and myonuclear number in rat soleus muscle</article-title><source>J Appl Physiol</source><year>2005</year><volume>99</volume><fpage>1494</fpage><lpage>1499</lpage><pub-id pub-id-type="doi">10.1152/japplphysiol.00394.2005</pub-id></citation><citation citation-type="display-unstructured">Zhong H, Roy RR, Siengthai B, Edgerton VR (2005) Effects of inactivity on fiber size and myonuclear number in rat soleus muscle. J Appl Physiol 99:1494&#x02013;1499 <pub-id pub-id-type="pmid">15994244</pub-id></citation></ref></ref-list></back></article> 